Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
Study identifier:NIS-RSI-SYM-2006/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open-label non-interventional evaluation of efficacy of Symbicort® forte Turbuhaler 320/9 µg (budesonide / formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (budesonide / formoterol)in functional status improvement of patients with chronic obstructive pulmonary disease (COPD)
Medical condition
Chronic Obstructive Pulmonary Disease
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
743
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Feb 2007
Primary Completion Date: 01 Sept 2007
Study Completion Date: 01 Sept 2007
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Matjaz Flezar
Golnik Hospital
